Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) VP Theodore Alan Huizenga sold 480 shares of the stock in a transaction on Friday, May 26th. The shares were sold at an average price of $57.46, for a total value of $27,580.80. Following the completion of the transaction, the vice president now owns 9,366 shares of the company’s stock, valued at $538,170.36. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Theodore Alan Huizenga also recently made the following trade(s):

  • On Thursday, March 9th, Theodore Alan Huizenga sold 2,500 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $86.34, for a total value of $215,850.00.

Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) traded down 4.46% during mid-day trading on Friday, reaching $55.91. The company’s stock had a trading volume of 304,845 shares. The firm’s market cap is $2.37 billion. The company’s 50-day moving average is $60.18 and its 200 day moving average is $71.60. Ultragenyx Pharmaceutical Inc has a 12 month low of $46.52 and a 12 month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.71) by $0.08. During the same quarter in the previous year, the firm posted ($1.35) EPS. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc will post ($7.02) EPS for the current year.

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

ILLEGAL ACTIVITY NOTICE: “Ultragenyx Pharmaceutical Inc (RARE) VP Theodore Alan Huizenga Sells 480 Shares” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/05/26/ultragenyx-pharmaceutical-inc-rare-vp-theodore-alan-huizenga-sells-480-shares.html.

Large investors have recently modified their holdings of the company. FMR LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 3.9% in the first quarter. FMR LLC now owns 6,110,627 shares of the biopharmaceutical company’s stock valued at $414,178,000 after buying an additional 227,802 shares in the last quarter. Capital Research Global Investors increased its position in Ultragenyx Pharmaceutical by 1.1% in the third quarter. Capital Research Global Investors now owns 4,830,859 shares of the biopharmaceutical company’s stock valued at $342,701,000 after buying an additional 52,690 shares during the last quarter. BlackRock Inc. increased its position in Ultragenyx Pharmaceutical by 102,249.1% in the first quarter. BlackRock Inc. now owns 3,166,680 shares of the biopharmaceutical company’s stock valued at $214,637,000 after buying an additional 3,163,586 shares during the last quarter. Vanguard Group Inc. increased its position in Ultragenyx Pharmaceutical by 5.7% in the first quarter. Vanguard Group Inc. now owns 2,994,938 shares of the biopharmaceutical company’s stock valued at $202,997,000 after buying an additional 161,622 shares during the last quarter. Finally, Columbia Wanger Asset Management LLC increased its position in Ultragenyx Pharmaceutical by 5.3% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,237,825 shares of the biopharmaceutical company’s stock valued at $83,900,000 after buying an additional 62,209 shares during the last quarter. Institutional investors own 96.35% of the company’s stock.

Several brokerages recently issued reports on RARE. Cowen and Company reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 17th. Wedbush lowered their target price on Ultragenyx Pharmaceutical from $88.00 to $80.00 and set a “buy” rating for the company in a research report on Thursday, March 23rd. HC Wainwright reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, March 23rd. Canaccord Genuity reaffirmed a “buy” rating and set a $100.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Thursday, March 23rd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $109.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 17th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $83.00.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

12 Month Chart for NASDAQ:RARE

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.